Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 16/20 | 0.65 |
| ▸ | F13A1 | P00488 | 13/20 | 0.65 |
| ▸ | TGM1 | P22735 | 11/20 | 0.65 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899672 | 0.88 | TGM2 (0.66) | TGM2F13A1TGM1TGM3PTPN2 | |
| SCHEMBL6902536 | 0.86 | PTPN2 (0.51) | TGM2F13A1TGM1PTPN2PTPN1 | |
| SCHEMBL1871099 | 0.83 | TGM2 (0.61) | TGM2F13A1TGM1TGM3PTPN2 | |
| SCHEMBL6902596 | 0.79 | TGM2 (0.68) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL6899848 | 0.79 | TGM2 (0.62) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL1869819 | 0.79 | TGM2 (1.00) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL6900242 | 0.78 | NR1H2 (0.49) | TGM2F13A1MAPT | |
| SCHEMBL6901428 | 0.77 | LMNA (0.48) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL6901811 | 0.76 | F13A1 (0.72) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL6901071 | 0.75 | TGM2 (0.59) | TGM2F13A1TGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011060321-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2011-05-19 | — | — | WO | disclosed |